Gilead Sciences’ COVID-19 drug Veklury (remdesivir) saw some rare year-over-year sales growth while the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) saw an even rarer decline in sales in the third quarter of 2024 as the drug maker raised its 2024 sales guidance.
Gilead Gears Up For CAR-T Data At ASH As Competition Weighs On Yescarta
The drug maker said in its third quarter earnings report that competition from other therapeutic classes, particularly bispecifics, resulted in a slight decline of sales for the CAR-T.

More from Earnings
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
More from Therapy Areas
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
The UK giant is forecasting peak sales of $5bn plus